The Heart in Diabetes (HiD) conference brings together world renowned leaders in diabetes, obesity, and cardiorenal metabolic diseases to interpret state-of-the-art clinical data aimed at improving the care of complex patients with these comorbidities.

This year, the conference will continue to focus on cardiorenal and metabolic (CRM) diseases. The unique interactions between internationally recognized experts and community clinicians who manage patients with CRM conditions foster the development of evidence-based, holistic, and comprehensive management plans for very high-risk patients. Faculty and attendees come from a broad range of specialties, including endocrinology, cardiology, nephrology, and primary care. By increasing knowledge and understanding of the pathophysiologic and clinical overlap between diabetes, obesity, cardiovascular disease (CVD), chronic kidney disease (CKD), heart failure (HF), and obesity, the HiD Congress equips clinicians with strategies and tools to improve the care of people with multiple cardiorenal and metabolic disorders.

The program will blend didactic presentations with cross-specialty interactive discussion panels which will provide ample time for Q&A, addressing treatment modalities and practical implications, ultimately offering tools to improve patient outcomes. The meeting will cover a wide range of topics including Obesity and Diabetes impact on Heart and Kidney, Women’s Health, ASCVD, HF,CKD, Role of Digital & Technology, Cardiomyopathy, Diabetes & Obesity Management, Lipid Disorders, the role of hypercortisolism in CRM diseases and other emerging unique topics in the Cardio-Renal-Metabolic space.

 

Learning Objectives
 

Upon completion of this meeting, participants should be able to:

• Provide comprehensive management of obesity, including
complications such as hypertension, dyslipidemia, T2D,
CKD, and HF

• Understand the role of incretin-based therapies in
prevention of CKD, CVD, and strokes, in diabetes and
obesity

• Evaluate the evidence supporting the use of GLP1-RAs,
SGLT2 inhibitors, nonsteroidal MRAs, and other treatments
to reduce CKD, HF, and CVD and mortality in patients with
T2D

• Discuss the impact of obesity and diets on fatty liver, CKD,
CVD and HF

• Understand the grave outcome of MASH and emerging
therapies for this condition

• Evaluate the extent of vascular disease in diabetes, obesity,
and cardiometabolic syndrome

• Be able to assess cardiovascular risk with imaging and
biomarkers

• Describe optimal use of technology—specifically CGM—
and digital technology and their impact on diabetes and
CVD

• Describe new and evolving agents in dyslipidemia
treatment and how they can be used to reduce ASCVD

• Describe the state of unique women health issues

​

Target Audience

​

This educational initiative is designed for cardiologists, endocrinologists, nephrologists, diabetologists, internists, family physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in the prevention and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

 

 

 

 

 

 

 

 

 

 

 

 

​